http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106075429-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295 |
filingDate | 2016-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2020-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2020-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-106075429-B |
titleOfInvention | Goat pox, sheep pox and aphtha triple cell attenuated vaccine and preparation method and application thereof |
abstract | The invention discloses a goat pox, sheep pox and aphtha triple cell attenuated vaccine and a preparation method and application thereof. The active ingredients of the Goatpox, the sheep pox and the Orf triple cell attenuated vaccine are goat pox Virus, sheep pox Virus and sheep infective pustule Virus cells which are obtained by self-separation and successive attenuated culture of the inventor and are passaged to cause attenuated Virus or passage Virus thereof, wherein the goat pox Virus is Goatpox Virus HN-XY2010F43 strain, the sheep pox Virus is Sheeppox Virus GS-WW 2010F44 strain, and the sheep infective pustule Virus is Orf Virus HB-TS09F65 strain. The result of the challenge protection test shows that the prepared goatpox, sheep pox and aphtha triple cell attenuated vaccine is safe and can generate effective immune protection. The invention has important practical significance for developing safe and efficient goat pox, sheep pox and aphtha triple cell attenuated vaccines and preventing and controlling goat pox and aphtha. |
priorityDate | 2016-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.